Literature DB >> 19438849

Increase in basal cell carcinoma incidence steepest in individuals with high socioeconomic status: results of a cancer registry study in The Netherlands.

S van Hattem1, M J Aarts, W J Louwman, H A M Neumann, J W W Coebergh, C W N Looman, T Nijsten, E de Vries.   

Abstract

BACKGROUND: Development of both basal cell carcinoma (BCC) and cutaneous malignant melanoma (MM) is associated with acute and intermittent sun exposure. In contrast to MM, the association between socioeconomic status (SES) and BCC is not well documented.
OBJECTIVES: To investigate the incidence of BCC according to SES, stratifying by age and tumour localization in a large population-based cohort. To assess changes over time in the distribution of the patients with BCC across the SES categories.
METHODS: All patients with a histologically confirmed first primary BCC (n = 27,027) diagnosed between 1988 and 2005 in the Southeast of The Netherlands were stratified by sex, age (25-44, 45-64 and > or = 65 years), period of diagnosis, SES category (based on income and value of housing) and localization of the BCC. Age-standardized BCC incidence rates were calculated for the year 2004 by SES category and localization. Ordinal regression was used to assess changes over time in the proportion of patients with BCC by sex, age and SES.
RESULTS: For men in all age groups higher BCC incidence in the highest SES category was observed, which remained significant after stratification for tumour localization. For women a consistent relationship was found only in younger women (< 65 years) for truncal BCCs, which occurred more frequently in high SES groups. Between 1990 and 2004, the proportion of BCC patients with high SES increased (+6%) and the proportion with low SES decreased (-7%).
CONCLUSIONS: High SES is associated with increased incidence of BCC among men. Our data suggest that BCC is changing from a disease of the poor to a disease of the rich.

Entities:  

Mesh:

Year:  2009        PMID: 19438849     DOI: 10.1111/j.1365-2133.2009.09222.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Patient Factors and Their Association with Nonmelanoma Skin Cancer Morbidity and the Performance of Self-skin Exams: A Cross-Sectional Study.

Authors:  Kyle T Amber; Romi Bloom; Mohammad-Ali Yazdani Abyaneh; Leyre A Falto-Aizpurua; Martha Viera; Martin N Zaiac; Keyvan Nouri; Shasa Hu
Journal:  J Clin Aesthet Dermatol       Date:  2016-09-01

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.

Authors:  Jo Ann LeQuang
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

3.  Skin cancer risk perceptions: a comparison across ethnicity, age, education, gender, and income.

Authors:  Kesha J Buster; Zhiying You; Mona Fouad; Craig Elmets
Journal:  J Am Acad Dermatol       Date:  2011-08-27       Impact factor: 11.527

4.  The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.

Authors:  Mara Ozolins; Hywel C Williams; Sarah J Armstrong; Fiona J Bath-Hextall
Journal:  Trials       Date:  2010-04-21       Impact factor: 2.279

5.  Clinical and pathological features associated with high-risk, multiple, and recurrent basal cell carcinomas: a retrospective cohort analysis from the Levantine coast of the Mediterranean Sea.

Authors:  Boutros Soutou; Carine Massih; Ghassan Sleilaty; Viviane Trak-Smayra; Marwan Nasr; Josiane Helou; Nabil Hokayem; Fady Ferran; Fadi H Sleilati; Farid Stéphan; Maya Halabi-Tawil; Roland Tomb
Journal:  Arch Dermatol Res       Date:  2022-01-21       Impact factor: 3.017

6.  Cumulative solar ultraviolet radiation exposure and basal cell carcinoma of the skin in a nationwide US cohort using satellite and ground-based measures.

Authors:  Mark P Little; Martha S Linet; Michael G Kimlin; Terrence Lee; Zaria Tatalovich; Alice J Sigurdson; Elizabeth K Cahoon
Journal:  Environ Health       Date:  2019-12-27       Impact factor: 5.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.